Beta test rollout. This site is in community QA — please send feature requests, bug reports and data corrections on the Feedback page or on GitHub.

Home
    Disclaimer
    MAL molecular structure

    MAL Stats & Data

    Methallylescaline
    NPS DataHub
    MW251.33
    FormulaC14H21NO3
    CAS207740-41-8
    IUPAC2-[3,5-dimethoxy-4-(2-methylprop-2-enoxy)phenyl]ethanamine
    SMILESNCCc1cc(OC)c(OCC(C)=C)c(OC)c1
    InChIKeyFOXJFBFFGULACD-UHFFFAOYSA-N
    Phenethylamines; Tryptamines; 2020/1. Von 2-Phenethylamin abgeleitete Verbindungen; 2021/1. Von 2-Phenethylamin abgeleitete Verbindungen; 2022/1. Von 2-Phenethylamin abgeleitete Verbindungen
    Chemical Class Scaline phenethylamine
    Psychoactive Class Psychedelic
    Half-Life Unknown (no human pharmacokinetic data)

    Receptor Profile

    Receptor Actions

    Agonists
    5-HT2A receptor agonist (partial)
    5-HT2C receptor agonist

    Toxicity

    PsychonautWiki

    The toxicity and long-term health effects of recreational methallylescaline use do not seem to have been studied in any scientific context and the exact toxic dose is unknown. This is because methallylescaline is a research chemical with very little history of human usage. Anecdotal evidence suggests that there are no negative health effects attributed to simply trying the substance by itself at low to moderate doses and using it very sparingly (but nothing can be completely guaranteed). Independent research should always be done to ensure that a combination of two or more substances is safe before consumption. It is strongly recommended that one use harm reduction practices when using this substance.

    Effect Profile

    Curated + 12 Reports
    Psychedelic 9.2

    Strong visuals, headspace, and auditory effects with moderate body load

    Visual Intensity×3
    10
    Headspace Depth×3
    10
    Auditory Effects×1
    10
    Body Load / Somatic Effects×1
    6

    Community Effects

    TripSit
    Positive
    visual enhancement
    Negative
    amnesia

    Tolerance & Pharmacokinetics

    drugs.wiki
    Half-Life
    Unknown (no human pharmacokinetic data)
    Addiction Potential
    Very low; not reported to be habit-forming or addictive.

    Tolerance Decay

    Full tolerance 1d Half tolerance 7d Baseline ~14d

    Rapid tolerance develops to classical psychedelics and cross‑tolerance is well‑documented between LSD and mescaline; MAL is inferred to follow a similar 5‑HT2A‑mediated pattern. Values above are heuristic for planning intervals, not pharmacokinetic half‑life. Data quality primarily anecdotal with inference from classic literature.

    Cross-Tolerances

    LSD
    70% ●○○
    Mescaline
    70% ●○○
    2C‑x phenethylamines
    60% ●○○
    DOx phenethylamines
    60% ●○○

    Experience Report Analysis

    Erowid
    21 Reports
    12 Single-substance
    2012–2025 Date Range
    21 With Age Data
    17 Effects Detected

    Demographics

    Gender Distribution

    Age Distribution

    Reports Over Time

    Effect Analysis

    Erowid

    Effects aggregated from 12 experience reports (12 single-substance Erowid)

    12 Reports
    17 Effects Detected
    9 Positive
    7 Adverse
    1 Neutral

    Effect Sentiment Distribution

    Confidence Distribution

    Each bar is the share of reports mentioning the effect; its whisker, and the band on the rows below, is the 95% interval: where the share could plausibly be with other reports of the same kind.

    Too few reports for bars: these effects come from 12 single-substance Erowid reports, and a bar is drawn only from 20 reports or more. With fewer, a percentage cannot tell a common effect from a rare one. Counts are shown instead. Why 20?

    Positive Effects 9

    Visual Distortions 11 of 12 70%
    Stimulation 8 of 12 70%
    Color Enhancement 7 of 12 70%
    Body High 6 of 12 70%
    Empathy 5 of 12 70%
    Music Enhancement 5 of 12 70%
    Euphoria 3 of 12 70%
    Introspection 3 of 12 70%
    Closed-Eye Visuals 3 of 12 70%

    Adverse Effects 7

    Anxiety 8 of 12 70%
    Nausea 8 of 12 70%
    Muscle Tension 5 of 12 70%
    Confusion 4 of 12 70%
    Pupil Dilation 4 of 12 70%
    Jaw Clenching 3 of 12 70%
    Headache 3 of 12 70%

    Dosage Distribution

    Dose distribution from experience reports, one dose per report (the first listed). Values above Q3 + 3×IQR are left out as outliers.

    Median: 45.0 mg IQR: 30.0–58.5 mg n=11

    Real-World Dose Distribution

    62K Doses

    From 25 individual dose entries. Values above Q3 + 3×IQR are left out as outliers.

    Oral (n=23)

    Median: 30.0mg 25th: 13.5mg 75th: 50.0mg 90th: 62.4mg

    Common Combinations

    Most co-occurring substances, as a share of all 21 reports filed under MAL; whiskers are 95% intervals

    Form / Preparation

    Most common forms and preparations, as a share of the 12 reports that give one

    Too few reports for bars: these forms come from 12 reports, and a bar is drawn only from 20 reports or more. With fewer, a percentage cannot tell a common effect from a rare one. Counts are shown instead. Why 20?

    • Powder / Crystals 6 of 12
    • Liquid 3 of 12
    • Capsule 3 of 12

    Body-Weight Dosing

    Dose per kg of body weight, one dose per report (the first listed), from reports giving a weight of 30–250 kg. Values above Q3 + 3×IQR are left out as outliers.

    Median: 0.584 mg/kg IQR: 0.345–0.858 mg/kg n=11

    Redose Patterns

    Redosing behavior across 13 reports

    2 of 13 Redosed
    1.3 Avg Doses
    15m Median Interval

    Too few reports for a chart: redosing is known from 13 reports, and a split is drawn only from 20 reports or more. Counts are shown instead. Why 20?

    • Single dose 11 of 13
    • Redosed 2 of 13

    Harm Reduction

    drugs.wiki

    - Identity and nomenclature: MAL is 3,5-dimethoxy-4-methallyloxyphenethylamine; the methallyl (2‑methylallyl) ether at the 4-position makes it an escaline-family analogue. This specific naming helps distinguish it from mescaline analogues with 3,4,5-trimethoxy patterns. (Source: PiHKAL·info entry and IUPAC listing).

    - Very slow, sometimes deceptive onset (60–120 min) is frequently reported; premature redosing is a common cause of excessive body-load and adverse effects—avoid any redose before 3 hours and consider split-dosing only after prior experience. (Anecdotal consensus across BL/Erowid).

    - Long duration (10–16 h) plus residual after-effects can impact sleep and next-day function; don’t drive, cycle, swim, or operate machinery during and after. Plan an unhurried, temperature‑controlled setting with trusted support.

    - Nausea and GI cramping are common in the first hours; bland pre-meal, ginger/peppermint, and avoiding heavy fats can help. Some find sublingual/insufflation reduces nausea but increases stimulation and local irritation. (Anecdotal).

    - Peripheral stimulation/vasoconstriction and mild hypertension can occur; combining with stimulants (including high-dose caffeine) increases cardiovascular strain—avoid such mixes, especially if you have cardiovascular risk factors. (General HR + TripSit chart rationale).

    - Urinary retention has been repeatedly reported anecdotally with moderate–high doses; inability to void for many hours is a red flag. Avoid anticholinergics (e.g., diphenhydramine), stay hydrated with electrolytes, and seek urgent care if painful retention persists (>6–8 h), if there’s flank pain, or if you feel systemically unwell. Do not self‑medicate with prescription alpha‑blockers without medical supervision. (Anecdotal; community warnings).

    - Salt forms: “MAL fumarate” has appeared in drug checking contexts and can be laid on blotter. Salt form changes mg‑for‑mg potency by mass; if unknown, titrate from the low end and do an allergy test with each new batch.

    - Reagent/drug checking: MAL has been found on blotter, a format often used for long‑acting phenethylamines; always test. Reagents may not be definitive; GC/MS (e.g., DrugsData) or a local service provides confirmation.

    - Allergy test: For any new batch, especially RCs, start with 1–2 mg to screen idiosyncratic reactions, then stepwise titrate on a different day.

    - Mental set: As with other psychedelics, strong alterations in thought and perception occur; having a sober sitter, a plan for anxiety management (breathing, environment control), and avoiding emotionally charged settings reduces risk.

    - Medical cautions: People with BPH/prostate issues, urinary tract problems, uncontrolled hypertension, or significant cardiovascular disease should avoid MAL without medical clearance due to retention and BP risks.

    - Do not mix with lithium (seizure/coma risk reported with psychedelics) or MAOIs (unpredictable potentiation and hypertension risk). Tramadol is risky due to serotonergic and seizure‑threshold effects.

    - Hydration: Sip fluids regularly; add electrolytes if sweating or active. Overhydration can be harmful—avoid chugging large volumes rapidly.

    - Sleep protection: Expect sleep disruption; prepare a dark, quiet space and non-pharmacologic sleep hygiene rather than sedative stacking post‑trip.

    ← Back to MAL